AR035970A1 - 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos - Google Patents
2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentosInfo
- Publication number
- AR035970A1 AR035970A1 ARP020101722A ARP020101722A AR035970A1 AR 035970 A1 AR035970 A1 AR 035970A1 AR P020101722 A ARP020101722 A AR P020101722A AR P020101722 A ARP020101722 A AR P020101722A AR 035970 A1 AR035970 A1 AR 035970A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- het2
- het1
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
2-amino-benzoxazol sulfonamidas que tienen la fórmula (1), un N-óxido, sal, forma estereoisomérica, mezclas racémicas, prodroga, éster o metabolito del mismo, en la cual R1 y R8 son, independientemente entre sí, hidrógeno, alquilo C1-6, alquenilo C2-6, arilalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-6, arilo, Het1, Het1-alquilo C1-6, Het2, o Het2-alquilo C1-6; R1 también puede ser un radical de fórmula (R11a)(R11b)N-C(R10a)(R10b)-CHR9- en la cual R9, R10a y R10b son, independientemente entre sí, hidrógeno, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, o alquilo C1-4 opcionalmente sustituido con arilo, Het1, Het2, cicloalquilo C3-7, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, aminosulfonilo, alquil C1-4S(O)t, hidroxi, ciano, halógeno o amino opcionalmente mono- o disustituido, donde los sustituyentes se seleccionan, independientemente entre sí, del grupo formado por alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; con lo cual R9, R10a y los átomos de carbono a los cuales están fijados pueden formar también un radical cicloalquilo C3-7; cuando L es -O-alcanodiilo C1-6-C(=O)- ó -NR8-alcanodiilo C1-6-C(=O)-, entonces R9 puede ser también oxo; R11a es hidrógeno, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo, aminocarbonilo opcionalmente mono- o disustituido, aminoalquilcarboniloxi C1-4 opcionalmente mono- o disustituido, alquiloxicarbonilo C1-4, ariloxicarbonilo, Het1-oxicarbonilo, Het2-oxicarbonilo, ariloxicarbonilalquilo C1-4, aril alquiloxicarbonilo, C1-4, alquilcarbonilo C1-4, cicloalquilcarbonilo C3-7, cicloalquil C3-7 alquiloxicarbonilo C1-4, cicloalquilcarboniloxi C3-7, carboxialquilcarboniloxi C1-4, alquilcarboniloxi C1-4, arilalquilcarboniloxi C1-4, arilcarboniloxi, ariloxicarboniloxi, Het1-carbonilo, Het1-carboniloxi, Het1-alquiloxicarbonilo C1-4, Het2-carboniloxi, Het2-alquilcarboniloxi C1-4, Het2-alquiloxicarboniloxi C1-4 o alquilo C1-4 opcionalmente sustituido con arilo, ariloxi, Het2, halógeno o hidroxi; donde los sustituyentes en los grupos amino se seleccionan independientemente entre sí, del grupo formado por alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; R11b es hidrógeno, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, arilo, Het1, Het2 o alquilo C1-4 opcionalmente sustituido con halógeno, hidroxi, alquil C1-4 S(O)t, arilo, cicloalquilo C3-7, Het1, Het2, amino opcionalmente mono- o disustituido, donde los sustituyentes, independientemente entre sí, se seleccionan del grupo formado por alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; donde R11b puede estar unido al resto de la molécula a través de un grupo sulfonilo; t es independientemente entre sí 0, 1 ó 2; R2 es hidrógeno o alquilo C1-6; L es -C(=O)-, -O-C(=O)-, -NR8-C(O)-, -O-alcanodiil C1-6-C(=O)-, -NR8-alcanodiil C1-6-C(=O)-, -S(=O)2-, -O-S(=O)2-, -NR8-S(=O)2, donde ya sea el grupo C(=O) o el grupo S(=O)2 está unido a la porción NR2; y con lo cual la porción alcanodiilo C1-6 está opcionalmente sustituida con hidroxi, arilo, Het1 y Het2; R3 es alquilo C1-6, arilo, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4 o arilalquilo C1-4; R4 es hidrógeno, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6 o alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados, independientemente entre sí, del grupo formado por arilo, Het1, Het2, cicloalquilo C3-7, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4) aminocarbonilo, aminosulfonilo, alquil C1-4 S(=O)t, hidroxi, ciano, halógeno y amino opcionalmente mono- o disustituido, donde los sustituyentes se seleccionan, independientemente entre sí, del grupo formado por alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; R5 es hidrógeno ó alquilo C1-6; R6 es hidrógeno o alquilo C1-6; composición farmacéutica, método "in vitro" para inhibir la replicación retroviral y utilización de estos compuestos en la manufactura de medicamentos. Los compuestos de fórmula (1) son utilizados como inhibidores de la proteasa aspártica, en particular de la proteasa HIV, de allí su acción inhibitoria sobre el virus del SIDA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01201732 | 2001-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035970A1 true AR035970A1 (es) | 2004-07-28 |
Family
ID=8180286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101722A AR035970A1 (es) | 2001-05-11 | 2002-05-10 | 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7622490B2 (es) |
| EP (1) | EP1387842B1 (es) |
| JP (1) | JP4467889B2 (es) |
| KR (1) | KR100878853B1 (es) |
| CN (1) | CN100549007C (es) |
| AP (1) | AP1652A (es) |
| AR (1) | AR035970A1 (es) |
| AT (1) | ATE429431T1 (es) |
| AU (1) | AU2002310818B2 (es) |
| BG (1) | BG66350B1 (es) |
| BR (1) | BR0209594A (es) |
| CA (1) | CA2444895C (es) |
| CY (1) | CY1109247T1 (es) |
| CZ (1) | CZ304524B6 (es) |
| DE (1) | DE60232067D1 (es) |
| DK (1) | DK1387842T3 (es) |
| EA (1) | EA009590B1 (es) |
| EE (1) | EE05307B1 (es) |
| ES (1) | ES2325809T3 (es) |
| HK (1) | HK1062912A1 (es) |
| HR (1) | HRP20031026B1 (es) |
| HU (1) | HUP0400438A3 (es) |
| IL (1) | IL158093A0 (es) |
| MX (1) | MXPA03010258A (es) |
| NO (1) | NO326883B1 (es) |
| NZ (1) | NZ529250A (es) |
| OA (1) | OA13134A (es) |
| PL (1) | PL209029B1 (es) |
| PT (1) | PT1387842E (es) |
| SK (1) | SK287952B6 (es) |
| WO (1) | WO2002092595A1 (es) |
| ZA (1) | ZA200307799B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| WO2003064406A1 (en) | 2002-01-07 | 2003-08-07 | Sequoia Pharmaceuticals | Resistance-repellent retroviral protease inhibitors |
| US7157489B2 (en) | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| BRPI0414916A (pt) * | 2003-09-30 | 2006-11-07 | Tibotec Pharm Ltd | métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos |
| US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
| US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
| UA85567C2 (en) | 2003-12-23 | 2009-02-10 | Тиботек Фармасьютикелз Лтд. | Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
| AU2004309122B2 (en) | 2003-12-23 | 2011-07-21 | Janssen Sciences Ireland Unlimited Company | Process for the preparation of (3R,3aS,6AR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
| CA2566340C (en) * | 2004-05-07 | 2014-05-06 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| BRPI0607827B8 (pt) | 2005-02-25 | 2021-05-25 | Janssen R & D Ireland | composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso |
| AR053845A1 (es) * | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
| WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8204879D0 (sv) | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
| EP0445926B1 (en) | 1990-03-09 | 1996-08-21 | Milliken Research Corporation | Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE154800T1 (de) * | 1992-08-25 | 1997-07-15 | Searle & Co | N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren |
| PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| ES2127938T3 (es) * | 1993-08-24 | 1999-05-01 | Searle & Co | Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas. |
| DK0721331T3 (da) | 1993-10-01 | 2002-02-11 | Astrazeneca Ab | Fremgangsmåde |
| CA2210889C (en) | 1995-01-20 | 2007-08-28 | G.D. Searle & Co. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
| US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| PL184771B1 (pl) | 1995-03-10 | 2002-12-31 | Searle & Co | Związek stanowiący hydroksyetyloaminosulfonamid pirolidynokarbonyloaminokwasu, kompozycja zawierająca ten związek, jego zastosowanie do wytwarzania kompozycji do leczenia infekcji retrowirusowej i sposób zapobiegania replikacji retrowirusa in vitro |
| US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| AU7722296A (en) * | 1995-11-15 | 1997-06-05 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
| EE03902B1 (et) | 1996-05-20 | 2002-12-16 | Janssen Pharmaceutica N.V. | Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend |
| ATE241969T1 (de) | 1997-03-26 | 2003-06-15 | Janssen Pharmaceutica Nv | Tabletten mit einem kern, der mit einem pilzbekämpfungsmittel und einem polymeren beschichtet ist |
| GB9717849D0 (en) | 1997-08-23 | 1997-10-29 | Seal Sands Chemicals Limited | Preparation of pyridene derivatives |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| ID25551A (id) | 1997-12-24 | 2000-10-12 | Vertex Pharma | Bahan baku obat penghambat protease aspartil |
| AU2012199A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU2010299A (en) | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| DK1088098T4 (en) | 1998-06-23 | 2015-09-14 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Fitnessassay and methods for reducing HIV resistance to therapy |
| AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
| PL367084A1 (en) * | 2001-04-09 | 2005-02-21 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors |
-
2002
- 2002-05-10 AU AU2002310818A patent/AU2002310818B2/en not_active Ceased
- 2002-05-10 HU HU0400438A patent/HUP0400438A3/hu not_active IP Right Cessation
- 2002-05-10 EA EA200301234A patent/EA009590B1/ru not_active IP Right Cessation
- 2002-05-10 AP APAP/P/2003/002904A patent/AP1652A/en active
- 2002-05-10 DE DE60232067T patent/DE60232067D1/de not_active Expired - Lifetime
- 2002-05-10 WO PCT/EP2002/005212 patent/WO2002092595A1/en active IP Right Grant
- 2002-05-10 CN CNB028097416A patent/CN100549007C/zh not_active Expired - Fee Related
- 2002-05-10 AT AT02735354T patent/ATE429431T1/de active
- 2002-05-10 EE EEP200300547A patent/EE05307B1/xx not_active IP Right Cessation
- 2002-05-10 PT PT02735354T patent/PT1387842E/pt unknown
- 2002-05-10 JP JP2002589479A patent/JP4467889B2/ja not_active Expired - Fee Related
- 2002-05-10 DK DK02735354T patent/DK1387842T3/da active
- 2002-05-10 BR BR0209594-7A patent/BR0209594A/pt not_active IP Right Cessation
- 2002-05-10 EP EP02735354A patent/EP1387842B1/en not_active Expired - Lifetime
- 2002-05-10 KR KR1020037013145A patent/KR100878853B1/ko not_active IP Right Cessation
- 2002-05-10 CA CA2444895A patent/CA2444895C/en not_active Expired - Fee Related
- 2002-05-10 CZ CZ2003-3290A patent/CZ304524B6/cs not_active IP Right Cessation
- 2002-05-10 MX MXPA03010258A patent/MXPA03010258A/es active IP Right Grant
- 2002-05-10 SK SK1490-2003A patent/SK287952B6/sk not_active IP Right Cessation
- 2002-05-10 OA OA1200300277A patent/OA13134A/en unknown
- 2002-05-10 US US10/474,485 patent/US7622490B2/en not_active Expired - Fee Related
- 2002-05-10 ES ES02735354T patent/ES2325809T3/es not_active Expired - Lifetime
- 2002-05-10 PL PL366780A patent/PL209029B1/pl unknown
- 2002-05-10 NZ NZ529250A patent/NZ529250A/en not_active IP Right Cessation
- 2002-05-10 IL IL15809302A patent/IL158093A0/xx not_active IP Right Cessation
- 2002-05-10 AR ARP020101722A patent/AR035970A1/es active IP Right Grant
-
2003
- 2003-10-06 ZA ZA2003/07799A patent/ZA200307799B/en unknown
- 2003-11-03 BG BG108309A patent/BG66350B1/bg unknown
- 2003-11-10 NO NO20034988A patent/NO326883B1/no not_active IP Right Cessation
- 2003-12-10 HR HRP20031026AA patent/HRP20031026B1/xx not_active IP Right Cessation
-
2004
- 2004-08-04 HK HK04105776.5A patent/HK1062912A1/xx not_active IP Right Cessation
-
2009
- 2009-07-21 CY CY20091100774T patent/CY1109247T1/el unknown
- 2009-10-07 US US12/575,216 patent/US7863306B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035970A1 (es) | 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR038172A1 (es) | Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento | |
| AR072149A1 (es) | Derivados de heteroaril-carboxamida | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| AR073450A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR043648A1 (es) | Derivados de bencenosulfonamida | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| AR089285A1 (es) | Derivados de betulina | |
| AR044518A1 (es) | Inhibidores de integrasa de hiv | |
| AR072184A1 (es) | Derivados de oxadiazol como agonistas del receptor s1p1 | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR065344A1 (es) | Derivados de azonia biciclo octano como activadores del receptor m3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |